HEALTH & LIFE SCIENCES NEWS
HEALTH & LIFE SCIENCES NEWS
Exploring critical business and legal issues across the healthcare and life sciences industries
HEALTH & LIFE SCIENCES NEWS
Exploring critical business and legal issues across the healthcare and life sciences industries

This Week in 340B: June 2 – 8, 2026

Posted In 340B

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary of relevant updates from the prior week in this industry-shaping body of litigation. Get more details on these 340B cases and all other material 340B cases pending in federal and state courts with the 340B Litigation Tracker.

Issues at Stake: Contract Pharmacy; Other

  • In a case against HRSA challenging its certification of a group of entities as 340B-eligible, the federal government and intervenor-defendant each filed a reply in support of the federal government’s motion for summary judgment.
  • In a case challenging the government’s rebate model pilot program, the plaintiff-appellees filed a brief regarding the district court’s denial of a motion to intervene filed by a group of drug manufacturers and a trade association of trade manufacturers.
  • In a case brought by a drug manufacturer challenging an Oregon state law governing contract pharmacy arrangements, intervenor Oregon Primary Care Association filed a reply in support of its cross-motion for summary judgment.
  • In a case brought by a drug manufacturer against the federal government, the intervenor-defendant filed a summary judgement reply brief and the defendant filed a reply in further support of the defendants’ motion for summary judgement.
  • In a consolidated case brought by a drug manufacturer and trade association for drug manufacturers challenging a Hawaii state law governing contract pharmacy arrangements, the third party filed a response in support of the third-party motion to quash.
Emily Jane Cook
Emily Cook is a practice area leader for McDermott's Healthcare Regulatory & Compliance practice. She is a national authority on the 340B drug pricing program, and also helps clients navigate the full suite of federal and state regulations that are essential to healthcare operations. Learn more about Emily's practice here.


Abygail Hoey
Abygail Hoey is a member of the Health & Life Sciences Practice Group, where she focuses her practice on healthcare transactions, as well as regulatory and compliance matters. Learn more about Abygail's practice here.


Sydney Merritt Martinez
Sydney Merritt Martinez focuses her practice on health law matters. Learn more about Sydney's practice here.


Kelsey Reinhardt
Kelsey R. Reinhardt focuses her practice on regulatory and transactional matters affecting a wide range of clients across the healthcare industry. Learn more about Kelsey's practice here.


Nadine Tejadilla
Nadine Tejadilla focuses her practice on transactional and regulatory matters in the health and life sciences industry. While in law school, Nadine served as a legal intern at a national nonprofit civil rights organization.Learn more about Nadine's practice here.

STAY CONNECTED

TOPICS

ARCHIVES

Chambers 2021 Top Ranked
U.S. News Law Firm of the Year 2022 Health Care Law
LEgal 500 EMEA top tier firm 2021
Legal 500 USA top tier firm